Argenx SE’s License Agreement with Zai Lab Limited


Baker McKenzie advised argenx SE on the deal.

Argenx SE signed a strategic collaboration and exclusive license agreement with Zai Lab Limited.

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

The Baker McKenzie team was led by Partners Koen Vanhaerents (Picture); Denis Segota (Corporate & Securities, New York); and Oren Livne (Corporate & Securities, New York). They were supported by a team comprised of Partners Thomas Rice (Corporate & Securities, New York); Clement Ngai (IP, Shanghai); Roel Meers (Corporate Finance, Brussels); Luc Meeus (Corporate Finance, Brussels); Dorothea Koo (M&A/Private Equity, Hong Kong) and Tracy Wut (M&A/Private Equity, Hong Kong); and associate Dr. iur. Julia Schieber (IP, Zurich).

Involved fees earner: Dorothea Koo – Baker McKenzie; Oren Livne – Baker McKenzie; Roel Meers – Baker McKenzie; Luc Meeus – Baker McKenzie; Clement Ngai – Baker McKenzie; Thomas Rice – Baker McKenzie; Julia Schieber – Baker McKenzie; Denis Segota – Baker McKenzie; Koen Vanhaerents – Baker McKenzie; Tracy Wut – Baker McKenzie;

Law Firms: Baker McKenzie;

Clients: argenx SE;